REGENCELL BIOSCIENCE HOLDING (RGC) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RGC • KYG7487R1002

27.715 USD
+0.48 (+1.78%)
At close: Feb 9, 2026
28.0757 USD
+0.36 (+1.3%)
Pre-Market: 2/10/2026, 8:36:48 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, RGC scores 2 out of 10 in our fundamental rating. RGC was compared to 191 industry peers in the Pharmaceuticals industry. RGC has a great financial health rating, but its profitability evaluates not so good. RGC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • RGC had negative earnings in the past year.
  • In the past 5 years RGC always reported negative net income.
  • In the past 5 years RGC always reported negative operating cash flow.
RGC Yearly Net Income VS EBIT VS OCF VS FCFRGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -54.68%, RGC is doing worse than 63.87% of the companies in the same industry.
  • With a Return On Equity value of -60.86%, RGC perfoms like the industry average, outperforming 47.12% of the companies in the same industry.
Industry RankSector Rank
ROA -54.68%
ROE -60.86%
ROIC N/A
ROA(3y)-46.27%
ROA(5y)-138.94%
ROE(3y)-48.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RGC Yearly ROA, ROE, ROICRGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGC Yearly Profit, Operating, Gross MarginsRGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • RGC has about the same amout of shares outstanding than it did 1 year ago.
  • RGC has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for RGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGC Yearly Shares OutstandingRGC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
RGC Yearly Total Debt VS Total AssetsRGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • There is no outstanding debt for RGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
RGC Yearly LT Debt VS Equity VS FCFRGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 42.68 indicates that RGC has no problem at all paying its short term obligations.
  • RGC's Current ratio of 42.68 is amongst the best of the industry. RGC outperforms 97.91% of its industry peers.
  • RGC has a Quick Ratio of 42.68. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 42.68, RGC belongs to the best of the industry, outperforming 97.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 42.68
Quick Ratio 42.68
RGC Yearly Current Assets VS Current LiabilitesRGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 100.00% over the past year.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
RGC Price Earnings VS Forward Price EarningsRGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGC Per share dataRGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0 0.01 0.01 0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RGC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REGENCELL BIOSCIENCE HOLDING

NASDAQ:RGC (2/9/2026, 8:00:02 PM)

Premarket: 28.0757 +0.36 (+1.3%)

27.715

+0.48 (+1.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-23
Earnings (Next)N/A
Inst Owners0.13%
Inst Owner Change2.95%
Ins Owners88.56%
Ins Owner Change0%
Market Cap13.70B
Revenue(TTM)N/A
Net Income(TTM)-4.09M
Analysts63.4
Price TargetN/A
Short Float %1.63%
Short Ratio1.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2039.4
P/tB 2039.4
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.68%
ROE -60.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.27%
ROA(5y)-138.94%
ROE(3y)-48.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 42.68
Quick Ratio 42.68
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.86%
Cap/Depr(5y)346.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.35%
OCF growth 3YN/A
OCF growth 5YN/A

REGENCELL BIOSCIENCE HOLDING / RGC FAQ

What is the fundamental rating for RGC stock?

ChartMill assigns a fundamental rating of 2 / 10 to RGC.


What is the valuation status for RGC stock?

ChartMill assigns a valuation rating of 0 / 10 to REGENCELL BIOSCIENCE HOLDING (RGC). This can be considered as Overvalued.


What is the profitability of RGC stock?

REGENCELL BIOSCIENCE HOLDING (RGC) has a profitability rating of 0 / 10.